Tempus AI Launches Next-Gen Agentic Platform to Accelerate Oncology Research

Tempus AI Inc. (NASDAQ:TEM) launched the next generation of Lens, an agentic AI platform designed to accelerate oncology drug development. By integrating Tempus' massive library of longitudinal real-world data, oncology foundation models, and computational infrastructure, the platform provides an end-to-end environment for research and trial design. It is already being used by 19 of the top 20 global biopharma companies.

The platform uses specialized "co-scientist" agents that allow users to propose complex biological hypotheses in plain language and receive targeted analysis plans. Once a plan is approved, these agents execute code-backed analyses against over 8.5 million de-identified patient records, delivering robust results in minutes. This process significantly reduces the time and manual expertise previously required for such tasks.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses AI to advance precision medicine. It achieves this through its massive libraries of clinical and genomic data. Pharmaceutical companies use their products to improve drug discovery processes while physicians use them to personalize treatments for their patients.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In conclusion, Tempus AI's next-gen agentic platform is a significant step forward in oncology research. Its contributions to the healthcare sector and drug development processes may play a crucial role in the future.